Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs Lyfe Rx

FuturHealth
Graded #215

Higher grade

vs+7.299999999999997
Lyfe Rx
Graded #375

Lower grade

The verdict

FuturHealth takes it — 65.6/100 to 58.3/100.

FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFuturHealth +10
60
50
Dose & formulationFuturHealth +17
81
64
Clinical oversightEven
67
67
Labs & monitoringFuturHealth +9
61
52
FulfillmentEven
62
62
Contract termsEven
55
55
FuturHealth · left barLyfe Rx · right bar

The numbers

MetricFuturHealthLyfe Rx
WeighScore65.6/10058.3/100
GradeCC
Scorecard rank#215#375
Semaglutide$199/mo (compounded)$225/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Lyfe Rx

Graded #375 · C

Strengths

  • Both compounded semaglutide and tirzepatide available
  • Delivery to all 50 states with 1–3 day pharmacy turnaround

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • Also sells non-prescription supplements ('Tirzepatide Weight Loss Supplement', 'Lipo Burn')
  • Shopify-based e-commerce storefront — less clinical infrastructure
  • FDA issued this company a warning letter dated 9 September 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard